Press Releases
- November 21, 2017 at 7:05 AM EST
- November 9, 2017 at 5:05 PM EST
- October 17, 2017 at 7:05 AM EDT
- September 29, 2017 at 7:05 AM EDT
Pagination
Displaying 1 - 10 of 34 results
Copyright West LLC. Minimum 15 minutes delayed.
Sign up to receive e-mail alerts whenever IMV Inc. posts new information to the site. Click here to choose your subscriptions.
IMV Inc. is a clinical-stage immuno-oncology company dedicated to making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV's proprietary drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. Lead product candidate DPX-Survivac is currently being evaluated in several clinical trials in advanced ovarian cancer in combination with other innovative immunotherapy agents.
© 2018 IMV Inc. All rights reserved.
130 Eileen Stubbs Avenue,
Suite 19
Dartmouth, Nova Scotia B3B 2C4
© 2018 IMV Inc. All rights reserved.